Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2017

01-01-2017 | Erratum

Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women

Authors: Lotte E. Elshof, Michael Schaapveld, Marjanka K. Schmidt, Emiel J. Rutgers, Flora E. van Leeuwen, Jelle Wesseling

Published in: Breast Cancer Research and Treatment | Issue 2/2017

Login to get access

Excerpt

In the original publication of the article, Fig. 1 was published incorrectly. The corrected Fig. 1 is given in this erratum. …
Metadata
Title
Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women
Authors
Lotte E. Elshof
Michael Schaapveld
Marjanka K. Schmidt
Emiel J. Rutgers
Flora E. van Leeuwen
Jelle Wesseling
Publication date
01-01-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4060-0

Other articles of this Issue 2/2017

Breast Cancer Research and Treatment 2/2017 Go to the issue

Epidemiology

Pre-diagnostic breastfeeding, adiposity, and mortality among parous Hispanic and non-Hispanic white women with invasive breast cancer: the Breast Cancer Health Disparities Study

Preclinical study

The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer

Preclinical study

Endocan as a prognostic biomarker of triple-negative breast cancer

Epidemiology

Up to one-third of breast cancer cases in post-menopausal Mediterranean women might be avoided by modifying lifestyle habits: the EPIC Italy study

Epidemiology

Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample

Preclinical study

Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits